Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 332 participants.

Also called NCT07276282

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 332 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07276282
  • EU CT 2024-520364-34-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Switzerland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07276282. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-19 (actual); primary completion 2028-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
Acronym
ZEPHYR
Condition
Acute Myocardial Infarction (AMI)
Condition
Coronary Atherosclerosis of Native Coronary Artery
Intervention (Drug)
Ziltivekimab
Intervention (Drug)
Placebo
Lead sponsor
ECRI bv (class: industry)
Collaborator
Novo Nordisk A/S (class: industry)
Collaborator
Insel Gruppe AG, University Hospital Bern (class: other)
Collaborator
Cardialysis B.V. (class: industry)

Record details

Record id
cardio:ct-nct07276282
Content hash
94f126083b5de0f7abb8ecef3f5051e7cba49f3a53376f38f643c85fb4688fb1